Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty

Arthroplasty, Replacement, Shoulder Clinical Trial

Official title:

Effect of Perioperative Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty for Osteoarthritis, in Terms of Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04507412
• Other study ID #: ORL-ORT- 020
• Status: Recruiting
• Phase: Phase 4
• Start date: September 9, 2020
• Est. completion date: August 31, 2032

Study information

• Verified date: September 2023
• Source: Ente Ospedaliero Cantonale, Bellinzona
• Contact: Christian Candrian, Prof.Dr.med
• Phone: +41 (0) 91 811 61 23
• Email: christian.candrian[@]eoc.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to evaluate if intravenous steroid supplementation can provide advantages over routine analgesia protocols in terms of post-operative symptoms (pain and nausea), length of hospital stay, shoulder range of motion, function and patient satisfaction

Description:

The purpose of this study is to detect the efficacy of intravenous perioperative steroid supplementation for total shoulder arthroplasty (TSA) surgeries in terms of short-term and long-term clinical outcomes and to demonstrate its advantages over the routine anaesthesia protocol. The comparison will be evaluated in terms of post- operative pain and function, opioids and analgesic drugs consumption, patient satisfaction, patient reported outcome measures (validated clinical scores), clinician-assessed clinical scores, systemic inflammatory response, length of hospital stay and long-term outcomes. Moreover, to confirm the safety of steroid supplementation all treatment related adverse events- and reactions are going to be recorded and reported, as well as post-operative glycaemia will be monitored. The primary objective of the study is to show the efficacy on post-operative pain of intravenous perioperative dexamethasone supplementation for TSA. The secondary objectives of the study are to show superiority by comparison of the intravenous peri- operative dexamethasone supplementation group to the routine analgesia protocol (no steroid supplementation group), in terms of post-operative pain and function, patient satisfaction, shoulder active- and passive range of motion, quantification with validated clinician- and patient reported outcome measures as the Constant, ASES and SSV Scores for function and EQ-5D-3L Score for health-related quality of life, opioids and analgesic drugs consumption, systemic inflammatory response, time until first mobilization and until the patient first slept through at night, the length of hospital stay and presence or absence of a frozen shoulder at the postoperative follow-up, as well as adverse events and reactions, in order to document the advantage over the absence of steroid supplementation in the short-, mid- term- and long-term follow up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 74
• Est. completion date: August 31, 2032
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 58 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients undergoing unilateral primary total anatomical or reverse shoulder arthroplasty (Total Shoulder Arthroplasty)
• Patients with a BMI >18.5 and <35
• Patients able to provide informed consent and follow all the study procedures as indicated by the protocol
• Informed Consent as documented by signature

Exclusion Criteria:

• Contraindications to steroids
• Revision and post-traumatic TSA
• Active steroid or immunosuppressive therapy in the last 30 days before the operation
• Pregnant or breast-feeding women
• Presence of other clinically significant concomitant disease states (ASA IV)
• Uncontrolled diabetes mellitus
• Contraindications to Non-steroidal anti-inflammatory drugs
• Chronic systemic diseases as immunodeficiency, autoimmune disease (Systemic Lupus Erythematosus), gout, rheumatic arthritis
• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
• Participation in another study with investigational drug within the 30 days preceding and during the present study
• Previous enrolment into the current study
• Enrolment of the investigator, his/her family members, employees and other dependent persons

Related Conditions & MeSH terms

• Arthroplasty, Replacement, Shoulder

Intervention

Drug:
• dexamethasone
perioperatively 9 mg i.v subministration

Locations

Country	Name	City	State
Switzerland	Christian Candrian	Lugano

Sponsors (1)

Lead Sponsor	Collaborator
Christian Candrian

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of serious adverse events related to steroid supplementation	Rate of serious adverse events related to steroid supplementation	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Other	Rate of prosthetic joint infections	Rate of prosthetic joint infections	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Other	Rate of wound infections	Rate of wound infections	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Other	Rate of wound healing problems	Rate of wound healing problems	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Primary	mean post-operative daily pain at rest	0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful	first 3 days after surgery
Secondary	Post-operative shoulder pain	0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful	first 3 months after surgery
Secondary	Post-operative shoulder pain	0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	Post-operative global shoulder function score	0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most functional	daily during the first 3 months
Secondary	Post-operative global shoulder function score	0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most functional	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	The clinician assessed Constant score	The Constant Score questionnaire consists of 8 questions (giving a score of 0 -100, with 100 being the best score) evaluating pain, activity level and range of motion	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES Score)	The ASES Score is a patient reported outcome measure (PROM), a validated score evaluating pain and function for daily living and leisure activity. A maximum of 100 points means maximum (normal) functionality and no pain. MCID is 13.6 ± 2.3 points after total shoulder prosthesis	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	The Subjective Shoulder Value (SSV)	The SSV is a percent of the subjective value of the shoulder given from the patient from 0-100%.	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	European Quality of Life-5 Dimensions-3 Level	"Health-Related Quality-of-Life Score" and is preferred evaluating cost utility analysis and changes in general health after surgical operations. It contains 5 questions and the maximum (best) score is 1. MCID is 0.07 units	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	PainDETECT	PainDETECT consists of seven questions that address the quality of pain symptoms; it is completed by the patient and no physical examination is required. A score =12 indicates that pain is unlikely to have a neuropathic component (< 15%), while a score of =19 suggests that pain is likely to have a neuropathic component (> 90%). An intermediate score (=13, =18) indicates a possible neuropathic component.	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	Patient satisfaction	0-10 numeric rating scale (NRS)	2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery
Secondary	Post-operative nausea	incidence and intensity (on a 0-10 NRS) will be evaluated. The 0-10 NRS is a valid and reliable instrument used for the self- assessment of symptoms: it consists in a single 11-point numeric scale, with 0 indicating no nausea and 10 reflecting the worst possible nausea	first 3 days post-operative days during hospitalisation
Secondary	Post-operative opioids and analgesic drugs consumption	Medication Quantification Scale (MQS) score. It is calculated for each medication by taking a consensus-based detriment weight for a given pharmacologic class and multiplying it by a score for dosage. The calculated values for each medication are then summed for a total MQS score. The score can provide a useful point measure of medication usage for any pain medication regime	first 3 days post-operative days during hospitalisation
Secondary	Postoperative inflammatory response	This outcome will be evaluated in terms of hematic C-Reactive Protein (CRP) and erythrocyte sedimentation rate (ESR) (the medical chart will be evaluated)	preoperatively and first 3 days post-operative days during hospitalisation
Secondary	Time from surgery to first mobilization	Time from surgery to first mobilization	During Hospitalization, approximately 1 days
Secondary	Rate of frozen shoulders	This is considered a complication occurring up to 11% and is induced by postoperative inflammatory processes that can lead to adhesive capsulitis	1 week post-operative during hospitalisation